Page last updated: 2024-08-03 04:53:38
th9507
Description
tesamorelin: a peptide; a stabilized analogue of the growth hormone releasing factor; aimed at reducing excess abdominal fat or VAT in lipodystrophy and HIV patients [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 16137828 |
| MeSH ID | M0457285 |
Synonyms (11)
| Synonym |
|---|
| th9507 |
| 218949-48-5 |
| tesamorelin |
| egrifta |
| tesamorelin [usan:inn] |
| mqg94m5eeo , |
| unii-mqg94m5eeo |
| gtpl6959 |
| (3e)-hex-3-enoylsomatoliberin |
| DTXSID00583207 |
| 804475-66-9 |
Research
Studies (56)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (30.36) | 29.6817 |
| 2010's | 34 (60.71) | 24.3611 |
| 2020's | 5 (8.93) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 21 (31.34%) | 5.53% |
| Reviews | 16 (23.88%) | 6.00% |
| Case Studies | 2 (2.99%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 28 (41.79%) | 84.16% |
Cardiovascular risk and dyslipidemia among persons living with HIV: a review.BMC infectious diseases, , 08-09, Volume: 17, Issue:1, 2017
Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:12, 2012
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:8, 2008
Effects of growth hormone-releasing factor in HIV-infected patients.The New England journal of medicine, , Feb-28, Volume: 358, Issue:9, 2008
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.PloS one, , Volume: 12, Issue:6, 2017
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.Current opinion in investigational drugs (London, England : 2000), , Volume: 7, Issue:10, 2006
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.AIDS (London, England), , 10-23, Volume: 31, Issue:16, 2017
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, , Volume: 37, 2017
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.JAMA, , Volume: 312, Issue:4
Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.The Journal of clinical endocrinology and metabolism, , 01-23, Volume: 106, Issue:2, 2021
Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.Current opinion in investigational drugs (London, England : 2000), , Volume: 11, Issue:10, 2010
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.PloS one, , Volume: 12, Issue:6, 2017
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:8, 2008
Cardiovascular risk and dyslipidemia among persons living with HIV: a review.BMC infectious diseases, , 08-09, Volume: 17, Issue:1, 2017
Growth hormone deficiency and human immunodeficiency virus.Best practice & research. Clinical endocrinology & metabolism, , Volume: 31, Issue:1, 2017
Therapeutic trial of growth hormone releasing factor in HIV patients.AIDS alert, , Volume: 23, Issue:4, 2008
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:8, 2008
Effects of growth hormone-releasing factor in HIV-infected patients.The New England journal of medicine, , Feb-28, Volume: 358, Issue:9, 2008
Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine, , Dec-06, Volume: 357, Issue:23, 2007
New lipodystrophy drug.AIDS patient care and STDs, , Volume: 21, Issue:4, 2007
Manipulation of the growth hormone axis in patients with HIV infection.The New England journal of medicine, , Dec-06, Volume: 357, Issue:23, 2007
TH9507: an experimental treatment for lipodystrophy.BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, ,Summer, Volume: 19, Issue:4, 2007
Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.Basic & clinical pharmacology & toxicology, , Volume: 100, Issue:1, 2007
Peptide may help with fat accumulation.AIDS patient care and STDs, , Volume: 17, Issue:9, 2003
The next generation of human growth hormone. How Serostim and tesamorelin measure up.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 19, Issue:5
Side effects and complications. Clinical trials of tesamorelin in Canada.TreatmentUpdate, , Volume: 19, Issue:3
Tesamorelin update.BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, , Volume: 22, Issue:4
Complications & side effects. Can TH9057 reduce fat deposits?TreatmentUpdate, , Volume: 16, Issue:7
14th annual retrovirus conference (CROI). Conference round-up. New lipo drug, rapid testing, and more news from CROI.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 18, Issue:3
Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 19, Issue:3
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.AIDS (London, England), , 10-23, Volume: 31, Issue:16, 2017
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:1, 2014
Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, , Volume: 21, Issue:3, 2011
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.Scientific reports, , 05-18, Volume: 11, Issue:1, 2021
Tesamorelin improves fat quality independent of changes in fat quantity.AIDS (London, England), , 07-15, Volume: 35, Issue:9, 2021
Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.The Journal of clinical endocrinology and metabolism, , 01-23, Volume: 106, Issue:2, 2021
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.JCI insight, , 08-20, Volume: 5, Issue:16, 2020
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging, , Volume: 8, Issue:3, 2019
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV, , Volume: 6, Issue:12, 2019
Tesamorelin, liver fat, and NAFLD in the setting of HIV.The lancet. HIV, , Volume: 6, Issue:12, 2019
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, , Volume: 37, 2017
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.AIDS (London, England), , 10-23, Volume: 31, Issue:16, 2017
Cardiovascular risk and dyslipidemia among persons living with HIV: a review.BMC infectious diseases, , 08-09, Volume: 17, Issue:1, 2017
Growth hormone deficiency and human immunodeficiency virus.Best practice & research. Clinical endocrinology & metabolism, , Volume: 31, Issue:1, 2017
Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.Journal of pharmacokinetics and pharmacodynamics, , Volume: 42, Issue:3, 2015
Treatment of dyslipidemia in HIV.Current atherosclerosis reports, , Volume: 17, Issue:4, 2015
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.Clinical pharmacokinetics, , Volume: 54, Issue:3, 2015
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 54, Issue:11, 2012
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.AIDS (London, England), , Jun-19, Volume: 25, Issue:10, 2011
Pathogenesis and treatment of HIV lipohypertrophy.Current opinion in infectious diseases, , Volume: 24, Issue:1, 2011
Recent FDA approvals and changes.AIDS patient care and STDs, , Volume: 25, Issue:2, 2011
Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue.Drugs of today (Barcelona, Spain : 1998), , Volume: 47, Issue:6, 2011
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Journal of acquired immune deficiency syndromes (1999), , Volume: 53, Issue:3, 2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extensThe Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:9, 2010
Therapeutic trial of growth hormone releasing factor in HIV patients.AIDS alert, , Volume: 23, Issue:4, 2008
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:8, 2008
Recent highlights in clinical AIDS research.The AIDS reader, , Volume: 18, Issue:2, 2008
Effects of growth hormone-releasing factor in HIV-infected patients.The New England journal of medicine, , Feb-28, Volume: 358, Issue:9, 2008
Manipulation of the growth hormone axis in patients with HIV infection.The New England journal of medicine, , Dec-06, Volume: 357, Issue:23, 2007
Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine, , Dec-06, Volume: 357, Issue:23, 2007
TH9507: an experimental treatment for lipodystrophy.BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, ,Summer, Volume: 19, Issue:4, 2007
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England), , Aug-12, Volume: 19, Issue:12, 2005
Peptide may help with fat accumulation.AIDS patient care and STDs, , Volume: 17, Issue:9, 2003
Side effects and complications. Tesamorelin--results from Phase III.TreatmentUpdate, , Volume: 19, Issue:3
Side effects and complications. Clinical trials of tesamorelin in Canada.TreatmentUpdate, , Volume: 19, Issue:3
Side effects and complications. Stimulating growth hormone.TreatmentUpdate, , Volume: 19, Issue:3
14th annual retrovirus conference (CROI). Conference round-up. New lipo drug, rapid testing, and more news from CROI.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 18, Issue:3
Complications & side effects. Can TH9057 reduce fat deposits?TreatmentUpdate, , Volume: 16, Issue:7
The next generation of human growth hormone. How Serostim and tesamorelin measure up.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 19, Issue:5
Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 19, Issue:3
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.JAMA, , Volume: 312, Issue:4
Tesamorelin update.BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, , Volume: 22, Issue:4
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.PloS one, , Volume: 10, Issue:10, 2015
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.The Annals of pharmacotherapy, , Volume: 46, Issue:2, 2012
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 54, Issue:11, 2012
Spotlight on tesamorelin in HIV-associated lipodystrophy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, , Dec-01, Volume: 25, Issue:6, 2011
Recent FDA approvals and changes.AIDS patient care and STDs, , Volume: 25, Issue:2, 2011
Pathogenesis and treatment of HIV lipohypertrophy.Current opinion in infectious diseases, , Volume: 24, Issue:1, 2011
Tesamorelin.Nature reviews. Drug discovery, , Volume: 10, Issue:2, 2011
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.Drugs, , May-28, Volume: 71, Issue:8, 2011
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Journal of acquired immune deficiency syndromes (1999), , Volume: 53, Issue:3, 2010
FDA approves tesamorelin for HIV-related lipodystrophy.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Dec-15, Volume: 67, Issue:24, 2010
Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.Current opinion in investigational drugs (London, England : 2000), , Volume: 11, Issue:10, 2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extensThe Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:9, 2010
Recent highlights in clinical AIDS research.The AIDS reader, , Volume: 18, Issue:2, 2008
A 39-year-old man with HIV-associated lipodystrophy.JAMA, , Sep-03, Volume: 300, Issue:9, 2008
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England), , Sep-12, Volume: 22, Issue:14, 2008
Good results for lipodystrophy drug.AIDS patient care and STDs, , Volume: 21, Issue:2, 2007
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.Current opinion in investigational drugs (London, England : 2000), , Volume: 7, Issue:10, 2006
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England), , Aug-12, Volume: 19, Issue:12, 2005
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.AIDS reviews, , Volume: 12, Issue:1
Cardiovascular risk and dyslipidemia among persons living with HIV: a review.BMC infectious diseases, , 08-09, Volume: 17, Issue:1, 2017
Treatment of dyslipidemia in HIV.Current atherosclerosis reports, , Volume: 17, Issue:4, 2015
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:8, 2008
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.Scientific reports, , 05-18, Volume: 11, Issue:1, 2021
Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.The Journal of clinical endocrinology and metabolism, , 01-23, Volume: 106, Issue:2, 2021
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.JCI insight, , 08-20, Volume: 5, Issue:16, 2020
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV, , Volume: 6, Issue:12, 2019
Tesamorelin, liver fat, and NAFLD in the setting of HIV.The lancet. HIV, , Volume: 6, Issue:12, 2019
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.PloS one, , Volume: 10, Issue:10, 2015
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.The Annals of pharmacotherapy, , Volume: 46, Issue:2, 2012
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 54, Issue:11, 2012
Tesamorelin.Nature reviews. Drug discovery, , Volume: 10, Issue:2, 2011
Recent FDA approvals and changes.AIDS patient care and STDs, , Volume: 25, Issue:2, 2011
Pathogenesis and treatment of HIV lipohypertrophy.Current opinion in infectious diseases, , Volume: 24, Issue:1, 2011
Spotlight on tesamorelin in HIV-associated lipodystrophy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, , Dec-01, Volume: 25, Issue:6, 2011
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.Drugs, , May-28, Volume: 71, Issue:8, 2011
FDA approves tesamorelin for HIV-related lipodystrophy.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Dec-15, Volume: 67, Issue:24, 2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extensThe Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:9, 2010
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Journal of acquired immune deficiency syndromes (1999), , Volume: 53, Issue:3, 2010
Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy.Current opinion in investigational drugs (London, England : 2000), , Volume: 11, Issue:10, 2010
Recent highlights in clinical AIDS research.The AIDS reader, , Volume: 18, Issue:2, 2008
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England), , Sep-12, Volume: 22, Issue:14, 2008
A 39-year-old man with HIV-associated lipodystrophy.JAMA, , Sep-03, Volume: 300, Issue:9, 2008
Good results for lipodystrophy drug.AIDS patient care and STDs, , Volume: 21, Issue:2, 2007
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.Current opinion in investigational drugs (London, England : 2000), , Volume: 7, Issue:10, 2006
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England), , Aug-12, Volume: 19, Issue:12, 2005
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.AIDS reviews, , Volume: 12, Issue:1
Cardiovascular risk and dyslipidemia among persons living with HIV: a review.BMC infectious diseases, , 08-09, Volume: 17, Issue:1, 2017
Treatment of dyslipidemia in HIV.Current atherosclerosis reports, , Volume: 17, Issue:4, 2015
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:8, 2008
Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:12, 2012
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extensThe Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:9, 2010
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.Scientific reports, , 05-18, Volume: 11, Issue:1, 2021
Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.The Journal of clinical endocrinology and metabolism, , 01-23, Volume: 106, Issue:2, 2021
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.JCI insight, , 08-20, Volume: 5, Issue:16, 2020
Tesamorelin, liver fat, and NAFLD in the setting of HIV.The lancet. HIV, , Volume: 6, Issue:12, 2019
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV, , Volume: 6, Issue:12, 2019
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.PloS one, , Volume: 12, Issue:6, 2017
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.Current opinion in investigational drugs (London, England : 2000), , Volume: 7, Issue:10, 2006
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, , Volume: 37, 2017
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.AIDS (London, England), , 10-23, Volume: 31, Issue:16, 2017
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.JAMA, , Volume: 312, Issue:4
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.PloS one, , Volume: 12, Issue:6, 2017
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:8, 2008
Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.The Journal of clinical endocrinology and metabolism, , 01-23, Volume: 106, Issue:2, 2021
Tesamorelin improves fat quality independent of changes in fat quantity.AIDS (London, England), , 07-15, Volume: 35, Issue:9, 2021
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.Scientific reports, , 05-18, Volume: 11, Issue:1, 2021
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.JCI insight, , 08-20, Volume: 5, Issue:16, 2020
Tesamorelin, liver fat, and NAFLD in the setting of HIV.The lancet. HIV, , Volume: 6, Issue:12, 2019
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV, , Volume: 6, Issue:12, 2019
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging, , Volume: 8, Issue:3, 2019
Growth hormone deficiency and human immunodeficiency virus.Best practice & research. Clinical endocrinology & metabolism, , Volume: 31, Issue:1, 2017
Cardiovascular risk and dyslipidemia among persons living with HIV: a review.BMC infectious diseases, , 08-09, Volume: 17, Issue:1, 2017
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.AIDS (London, England), , 10-23, Volume: 31, Issue:16, 2017
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, , Volume: 37, 2017
Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.Journal of pharmacokinetics and pharmacodynamics, , Volume: 42, Issue:3, 2015
Treatment of dyslipidemia in HIV.Current atherosclerosis reports, , Volume: 17, Issue:4, 2015
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.Clinical pharmacokinetics, , Volume: 54, Issue:3, 2015
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, , Volume: 54, Issue:11, 2012
Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue.Drugs of today (Barcelona, Spain : 1998), , Volume: 47, Issue:6, 2011
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.AIDS (London, England), , Jun-19, Volume: 25, Issue:10, 2011
Pathogenesis and treatment of HIV lipohypertrophy.Current opinion in infectious diseases, , Volume: 24, Issue:1, 2011
Recent FDA approvals and changes.AIDS patient care and STDs, , Volume: 25, Issue:2, 2011
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extensThe Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:9, 2010
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Journal of acquired immune deficiency syndromes (1999), , Volume: 53, Issue:3, 2010
Recent highlights in clinical AIDS research.The AIDS reader, , Volume: 18, Issue:2, 2008
Effects of growth hormone-releasing factor in HIV-infected patients.The New England journal of medicine, , Feb-28, Volume: 358, Issue:9, 2008
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.The Journal of clinical endocrinology and metabolism, , Volume: 93, Issue:8, 2008
Therapeutic trial of growth hormone releasing factor in HIV patients.AIDS alert, , Volume: 23, Issue:4, 2008
TH9507: an experimental treatment for lipodystrophy.BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, ,Summer, Volume: 19, Issue:4, 2007
Manipulation of the growth hormone axis in patients with HIV infection.The New England journal of medicine, , Dec-06, Volume: 357, Issue:23, 2007
Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine, , Dec-06, Volume: 357, Issue:23, 2007
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England), , Aug-12, Volume: 19, Issue:12, 2005
Peptide may help with fat accumulation.AIDS patient care and STDs, , Volume: 17, Issue:9, 2003
Tesamorelin update.BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, , Volume: 22, Issue:4
Side effects and complications. Tesamorelin--results from Phase III.TreatmentUpdate, , Volume: 19, Issue:3
Side effects and complications. Clinical trials of tesamorelin in Canada.TreatmentUpdate, , Volume: 19, Issue:3
Side effects and complications. Stimulating growth hormone.TreatmentUpdate, , Volume: 19, Issue:3
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.JAMA, , Volume: 312, Issue:4
14th annual retrovirus conference (CROI). Conference round-up. New lipo drug, rapid testing, and more news from CROI.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 18, Issue:3
Complications & side effects. Can TH9057 reduce fat deposits?TreatmentUpdate, , Volume: 16, Issue:7
Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 19, Issue:3
The next generation of human growth hormone. How Serostim and tesamorelin measure up.Positively aware : the monthly journal of the Test Positive Aware Network, , Volume: 19, Issue:5
Safety/Toxicity (5)
| Article | Year |
|---|
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.
PloS one, , Volume: 12, Issue:6 | 2017 |
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extens
The Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:9 | 2010 |
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Journal of acquired immune deficiency syndromes (1999), , Volume: 53, Issue:3 | 2010 |
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
AIDS (London, England), , Sep-12, Volume: 22, Issue:14 | 2008 |
Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.
Basic & clinical pharmacology & toxicology, , Volume: 100, Issue:1 | 2007 |
Pharmacokinetics (2)
Bioavailability (1)
Dosage (2)